secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0001140361-25-009362
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Roivant and Immunovant announce positive Phase 3 batoclimab MG results and initial Phase 2b CIDP results
--------------------------------------------------------------------------------

- Phase 3 MG study met primary endpoint with 5.6-point MG-ADL improvement at 12 weeks in high-dose batoclimab arm.
- Initial CIDP Phase 2b Period 1 data showed 1.8-point aINCAT improvement and 84% responder rate in patients with ≥70% IgG reduction.
- Immunovant plans to initiate registrational studies for IMVT-1402 in MG and CIDP.
- Deeper IgG reductions correlated with better clinical outcomes across both studies.
- Conference call held on March 19, 2025 at 8:00 a.m. ET to discuss results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036125009362/0001140361-25-009362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036125009362/ef20045740_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-009362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer